Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Preprint
Abstract
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar classKeywords
All Related Versions
- Published version: Multiple Sclerosis and Related Disorders, 80, 105100.
This publication has 28 references indexed in Scilit:
- New insights into the burden and costs of multiple sclerosis in EuropeMultiple Sclerosis Journal, 2017
- Cost–utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ diseaseEuropean Journal of Endocrinology, 2016
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod TreatmentJAMA Neurology, 2016
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet, 2016
- Fingolimod may support neuroprotection via blockade of astrocyte nitric oxideAnnals of Neurology, 2014
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2014
- Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosisAnnals of Neurology, 2013
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UKValue in Health, 2007
- Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell SurvivalJournal of Neuroscience, 2005